Managing urinary incontinence in older patients

Advanced Studies in Medicine

Volumn 5, Issue 10, 2005, Pages 537-545

  Harper, G Michael ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BULKING AGENT; COLLAGEN; DETROL IR; DETROL LA; DITROPAN XL; DULOXETINE; ESTROGEN; MEDROXYPROGESTERONE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; TOLTERODINE;

AGE; AGING; ANTICHOLINERGIC EFFECT; BEHAVIOR THERAPY; BLURRED VISION; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CONSULTATION; DISEASE EXACERBATION; DISEASE SEVERITY; EVALUATION; HUMAN; INDEPENDENCE; MICTURITION; MOTIVATION; NERVE STIMULATION; NURSING HOME PATIENT; PATIENT REFERRAL; PHYSICAL EXAMINATION; PREVALENCE; PRIMARY MEDICAL CARE; QUALITY OF LIFE; REVIEW; SACRAL NERVE STIMULATION; SYMPTOM; URINE INCONTINENCE; XEROSTOMIA;

EID: 33644666699     PISSN: 15303004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Reznicek SB. Management of incontinence in the elderly. J Gend Specif Med. 2002;5:43-48.
2. Wilson L, Brown JS, Shin GP, Luc KO, Subak LL. Annual direct cost of urinary incontinence. Obstet Gynecol. 2001;98:398-406.
3. Wagner TH, Hu TW. Economic costs of urinary incontinence in 1995. Urology. 1998;51:355-361.
4. Kirschstein R. Disease-specific estimates of direct and indirect costs of illness and NIH support: fiscal year 2000 update. Bethesda, Md: Department of Health and Human Services, National Institutes of Health, Office of the Director, February 2000. Available at: www1.ad.nih.gov/osp/ospp/ecostudies/ COIreportweb.htm. Accessed February 2, 2004.
5. Thom D. Variation in estimates of urinary incontinence prevalence in the community: effects of differences in definition, population characteristics, and study type. J Am Geriatr Soc. 1998;46:473-480.
6. Brawn JS, Grady D, Ouslander JG, et al. Prevalence of urinary incontinence and associated risk factors in postmenopausal women. Obstet Gynecol. 1999;94:66-70.
7. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of averactive bladder in the United States. World J Urol. 2003;20:327-336
8. Fantl J, Newman D, Colling J, DeLancey J, Keeys C, McDowell B. Urinary Incontinence in Adults: Acute and Chronic Management. Rockville, MD: Agency for Health Care Policy and Research, US Dept of Health and Human Services. Clinical Practice Guidelines No. 2, 1996 Update. AHCPR publication 96-0682; March 1996.
9. McGhan WF. Cast effectiveness and quality of life considerations in the treatment of patients with averactive bladder. Am J Manag Care. 2001;7(suppl 2):S62-75.
10. Klausner AP, Vapnek JM. Urinary incontinence in the geriatric population. Mt Sinoi J Med. 2003;70:54-61.
11. Miller M. Nocturnal polyuria in older people: pathophysiology and clinical implications. J Am Geriatr Soc. 2000;48:1321-1329.
12. Knutson T, Edlund C, Fall M, Dahlstrand C. BPH with coexisting overactive bladder dysfunction-an everyday urological dilemma. Neurourol Urodgyn. 2001;20:237-247.
13. Resnick NM, Yalla SV. Geriatric incontinence and voiding dysfunction. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, eds. Compbell's Urology. 7th ed. Philadelphia: WB Sounders Co; 1998:1045.
14. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the international Continence Society. Neurourol Urodyn. 2002;21:167-178.
15. Resnick NM, Yalla SV. Detrusor hyperactivity with impaired contractile function: an unrecognized but common cause of incontinence in elderly patients. JAMA. 1987;257:3076-3081.
16. Thakar R, Stanton S. Regular review: management of urinary incontinence in women. BMJ. 2000;321(7272):1326-1331.
17. Johnson TM 2nd, Ouslander JG. Urinary incontinence in the older man. Med Clin North Am. 1999;83:1247-1266.
18. Sampselle CM. Behavioral intervention: the first-line treatment for women with urinary incontinence. Curr Urol Rep. 2003;4:356-361.
19. Subak LL, Quesenberry CP, Posner SF, Cattolica E, Soghikian K. The effect of behavioral therapy on urinary incontinence: a randomized controlled trial. Obstet Gynecol. 2002;100:72-78.
20. Fantl JA, Wyman JF, McClish DK, et al. Efficacy of bladder training in older women with urinary incontinence. JAMA. 1991;265:609-613.
21. Burgio KL, Locher JL, Goode PS, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: o randomized controlled trial. JAMA. 1998;280:1995-2000.
22. Berghmans LC, Hendriks HJ, Bo K, Hay-Smith EJ, de Bie RA, van Waalwijk von Doom ES. Conservative treatment of stress urinary incontinence in women: a systematic review of randomized clinical trials. Br J Urol. 1998;82:181-191.
23. Goode PS, Burgio KL, Locher JL, et al. Effect of behavioral training with or without pelvic floor electrical stimulation on stress incontinence in women: a randomized controlled trial. JAMA. 2003;290:345-352.
24. Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc. 2000;48:370-374.
25. Lee JG, Hong JY, Choo MS, et al. Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder. Int J Urol. 2002;9:247-252.
26. Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 1999;10:283-289.
27. Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol. 1998;81:801-810.
28. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology. 1997;50(suppl 6A):90-96; discussion 97-99.
29. Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003;78:687-695.
30. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc. 2001;76:358-363
31. Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, Sanders SW. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003;62:237-242.
32. Holaska M, Ralph G, Weidemann A, et al. Controlled double-blind multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol. 2003;20:392-399.
33. Sanctura package insert. East Hanover, NJ. Odyssey Pharmaceuticals; 2004.July.
34. Chess-Williams R, Chapple CR, Yamanishi T, Yasuda K, Sellers DJ. The minor population of M3-receptors mediate contraction of human defrusor muscle in vitro. J Auton Pharmacol 2001;21:243-248.
35. Foote J, Glavind K, Kralidis G, Wyndaele J. Treatment of overactive bladder in the older patient: Pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol. 2005;48:471-477.
36. Zinner N, Tuttle J, Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol. 2005 Aug 12;[Epub ahead of print].
37. Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscorinic agent solifenacin succinate in patients with overactive bladder. J Urol. 2004;172:1919-1924.
38. Chapple CR, Arano P, Bosch JLHR, De Ridder D, Kramer AEJL, Ridders AM. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor aver-activity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int. 2004;93:71-77.
39. Moehrer B, Hextoll A, Jackson S. Oestrogens for urinary incontinence in women. Cochrane Database Syst Rev. 2003;2:CD001405.
40. Hendrix SL, Cochrane BB, Nygoard IE, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA. 2005;293:935-948.
41. Dmochowski RR, Miklos JR, Norton PA, Zinner NR, Yalcin I, Bump RC. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol. 2003;170:1259-1263.
42. van Kerrebroeck P, Abrams P, Longe R, et al. Duloxetine versus placebo in the treatment of European ond Canadian women with stress urinary incontinence. BJOG. 2004;111:249-257.
43. Millard RJ, Moore K, Rencken R, Yalcin I, Bump RC. Duloxetine vs placebo in the treatment of stress urinary incontinence: o four-continent randomized clinical trail. BJU Int 2004;93:311-318.
44. Norton PA, Zinner NR, Yalcin I, Bump RC. Duloxetine versus plocebo in the treatment of stress urinary incontinence. Am J Obsfer Gynecol. 2002;187:40-48.
45. Thor KB, Katofiasc MA. Effects of duloxetine, a combined serotonin and norepenephrine reuptake inhibitor, on central neural control of lower urinary tract function in chloraloseanesthetized female cat. J Pharmacol Exp Ther. 1995;274:1014-1024.
46. Bosch JLHR. The evolving role of the specialist in the diagnasis and management of the patient with OAB. Eur Urol Supp. 2002;1:17-22.
47. Corcos J, Fournier C. Periurethral collagen injection for the treatment of female stress urinary incontinence: 4-year follow-up results. Urology. 1999;54:815-818.
48. Gorton E, Stanton S, Mongo A, Wiskind AK, Lentz GM, Bland DR. Periurethral collagen injection: a long-term follow-up study. BJU Int. 1999;84:966-971.
49. Iselin CE. Periurethral collagen injections following radical prostatectomy: dos the patient benefit? Curr Opin Urol. 1999;9:209-212.
50. Lightner DJ. Review of the available urethral bulking agents. Curr Opin Urol. 2002;12:333-338.
51. Schmidt RA, Jonas U, Oleson KA, et al. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. J Urol. 1999;162:352-357.
52. Janknegt RA, Hassouna MM, Siegel SW, et al. Long-term effectiveness of sacral nerve stimulation for refractory urge incontinence. Eur Urol. 2001;39:101-106.
53. Abrams P, Blaivas JG, Fowler CJ, et al. The role of neuromodulation in the management of urinary urge incontinence. BJU Int. 2003;91:355-359.